FC
DNLI icon

FORA Capital’s Denali Therapeutics DNLI Stock Holding History

FORA Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,020
Closed -$115K – 932
2021
Q1 		$115K Buy
+2,020
New +$135K 0.04% 385
2020
Q4 		– Sell
-1,839
Closed -$66K – 964
2020
Q3 		$66K Buy
+1,839
New +$55.4K 0.04% 386

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

FORA Capital's DNLI Position: Q2 2021 in Review

FORA Capital sold out of Denali Therapeutics (DNLI) in Q2 2021, closing a stake of 2,020 shares — an estimated $115K sold.

FORA Capital first reported a position in DNLI in Q3 2020 and held it in 2 quarters. The position peaked at $115K in Q1 2021. 210 funds tracked by Wall St. Rank hold DNLI as of Q2 2021.

  • FORA Capital reported no remaining Denali Therapeutics position as of Q2 2021 after selling out during the quarter.
  • FORA Capital sold 2,020 Denali Therapeutics shares in Q2 2021, an estimated $115K.
  • FORA Capital first reported a position in Denali Therapeutics in Q3 2020 and held it in 2 quarters.
  • FORA Capital's Denali Therapeutics position peaked at $115K in Q1 2021.
  • 210 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2021.

Based on FORA Capital's 13F filing for Q2 2021, filed 16 Aug 2021.